Johnson & Johnson’s Heart Pump Trial Shows Promising Results for Cardiogenic Shock Patients

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-09-02 10:08:02

BTCCSquare news:

Johnson & Johnson's Impella CP heart pump demonstrated a 16.3% reduction in mortality risk and extended life expectancy by 1.6 years for cardiogenic shock patients in its decade-long DanGer Shock trial. The findings, published in the New England Journal of Medicine, mark a significant advancement in cardiac care technology.

The healthcare giant simultaneously presented results at the European Society of Cardiology Congress, reinforcing its position in medical innovation. This development coincides with J&J's planned $55 billion U.S. investment expansion over four years, signaling strategic growth in domestic pharmaceutical manufacturing.

By:

Log in to Reply

Suntory CEO Steps Down Amid Illegal Drug Probe, Denies Allegations

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.